Stereotactic Body Radiotherapy Without Systemic Therapy for Oligometastatic Cancer

What outcomes are associated with metastasis-directed stereotactic body radiotherapy (SBRT) without up-front systemic therapy in patients with oligometastatic cancer?In this systematic review and meta-analysis of 2074 unique patients from 29 unique studies, SBRT alone was associated with pooled 1- and-2-year systemic therapy–free survival (STFS) rate of 70% across cancer types. Subgroup analyses revealed the highest STFS rates in renal cell (87%) and prostate cancer (78%), with lower STFS rates in other cancer types.These findings suggest that metastasis-directed SBRT for oligometastatic disease was associated with clinically meaningful STFS, particularly in selected patients with prostate or renal cell cancer.

Corresponding Author: Jonas Willmann, MD, Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Rämistrasse 100, 8091 Zurich, Switzerland (jonas.willmann@usz.ch).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.